Literature DB >> 659625

Extrapancreatic glucagon and glucagonlike immunoreactivity in depancreatized dogs. A quantitative assessment of secretion rates and anatomical delineation of sources.

W A Muller, L Girardier, J Seydoux, M Berger, A E Renold, M Vranic.   

Abstract

The anatomical sites and the rates of extrapancreatic secretion of glucagon and of glucagon-like immunoreactivity (GLI) were assessed in dogs 2 h after pancreatectomy by catheterization of the gastrosplenic and mesenteric veins. Glucagon release from the gastrosplenic area approximated one-fourth that of a normal pancreas and rose from 0.25 to 1.0 ng/kg per min during arginine stimulation. Intestinal glucagon secretion was small and did not respond to arginine, suggesting that the stomach is the only important extrapancreatic source of glucagon. Glucagon concentrations attained by gastrosplenic secretion were in close proportion to those obtained during the administration of exogenous glucagon, indicating similar clearance rates of extrapancreatic and pancreatic glucagon, approximating 10 ml/kg per min.GLI secretion (0.3 ng eq/kg per min) was limited to the intestinal area and was transiently stimulated by arginine and exogenous glucagon. Base-line GLI clearance approximated 1 ml/kg per min. No insulin secretion could be detected. Gastrointestinal glucose uptake rose from 0.56 to 2.2 mg/kg per min after glucagon administration suggesting that as much as 10% of total glucose production can be taken up by the gastrointestinal tract. In two dogs both the stomach and pancreas were removed. Intestinal glucagon release remained small and did not increase during arginine administration. By contrast, GLI release was stimulated by both arginine and exogenous glucagon.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 659625      PMCID: PMC371745          DOI: 10.1172/JCI109096

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Evidence for the presence of glucagon-like immunoreactivity (GLI) in the pancreas.

Authors:  C B Srikant; R H Unger
Journal:  Endocrinology       Date:  1976-12       Impact factor: 4.736

2.  Gastric A-cell function in normal dogs.

Authors:  L Muñoz-Barragan; E Blazquez; G S Patton; R E Dobbs; R H Unger
Journal:  Am J Physiol       Date:  1976-10

3.  Large glucagon immunoreactivity in extracts of pancreas.

Authors:  D Rigopoulou; I Valverde; J Marco; G Faloona; R H Unger
Journal:  J Biol Chem       Date:  1970-02-10       Impact factor: 5.157

4.  Factors controlling gastric-glucagon release.

Authors:  P J Lefèbvre; A S Luyckx
Journal:  J Clin Invest       Date:  1977-04       Impact factor: 14.808

5.  Effects of exogenous glucagon and epinephrine in physiological amounts on the blood levels of free fatty acids and glycerol in dogs.

Authors:  W A Muller; T T Aoki; R H Egdahl; G F Cahill
Journal:  Diabetologia       Date:  1977-01       Impact factor: 10.122

6.  Porcine gastric insulin.

Authors:  C Kühl; S L Jensen; O V Nielsen
Journal:  Endocrinology       Date:  1976-12       Impact factor: 4.736

7.  Control of A and B cells in vivo by sympathetic nervous input and selective hyper or hypoglycemia in dog pancreas.

Authors:  L Girardier; J Seydoux; L A Campfield
Journal:  J Physiol (Paris)       Date:  1976-11

8.  Gastric A-cell function in insulin-deprived depancreatized dogs.

Authors:  E Blazquez; L Muñoz-Barragan; G S Patton; L Orci; R E Dobbs; R H Unger
Journal:  Endocrinology       Date:  1976-11       Impact factor: 4.736

9.  Measurement and partial characterization of immunoreactive glucagon in gastrointestinal tissues of dogs.

Authors:  S Morita; K Doi; C C Yip; M Vranic
Journal:  Diabetes       Date:  1976-11       Impact factor: 9.461

10.  Extraction, gel filtration pattern, and receptor binding of porcine gastrointestinal glucagon-like immunoreactivity.

Authors:  J J Holst
Journal:  Diabetologia       Date:  1977-04       Impact factor: 10.122

View more
  12 in total

Review 1.  Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.

Authors:  Roger H Unger; Alan D Cherrington
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

2.  Absence of islet alpha cell function in pancreatectomized patients.

Authors:  A Tiengo; M Bessioud; I Valverde; A Tabbi-Anneni; S Delprato; J Alexandre; R Assan
Journal:  Diabetologia       Date:  1982-01       Impact factor: 10.122

3.  Metabolic manifestations of insulin deficiency do not occur without glucagon action.

Authors:  Young Lee; Eric D Berglund; May-yun Wang; Xiaorong Fu; Xinxin Yu; Maureen J Charron; Shawn C Burgess; Roger H Unger
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-13       Impact factor: 11.205

4.  Adrenergic blockade alters glucose kinetics during exercise in insulin-dependent diabetics.

Authors:  D C Simonson; V Koivisto; R S Sherwin; E Ferrannini; R Hendler; A Juhlin-Dannfelt; R A DeFronzo
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

5.  Glucagon immunoreactivities and amino acid profile in plasma of duodenopancreatectomized patients.

Authors:  W A Muller; M Berger; P Suter; H J Cüppers; J Reiter; T Wyss; P Berchtold; F H Schmidt; J P Assal; A E Renold
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

6.  Plasma pancreatic glucagon response to blood glucose in experimental pancreatolithiasis in dogs.

Authors:  N Okumura; T Hayakawa; A Sakakibara; A Noda; T Kondo
Journal:  Diabetologia       Date:  1983-12       Impact factor: 10.122

7.  Identical biological effects of pancreatic glucagon and a purified moiety of canine gastric immunoreactive glucagon.

Authors:  K Doi; M Prentki; C Yip; W A Muller; B Jeanrenaud; M Vranic
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

8.  Effect of stimulation of endogenous glucagon secretion by amino acid administration on canine hepatic bile flow.

Authors:  D L Kaminski; Y Deshpande; M C Beinfeld
Journal:  Dig Dis Sci       Date:  1987-04       Impact factor: 3.199

Review 9.  Glucagon is the key factor in the development of diabetes.

Authors:  Young H Lee; May-Yun Wang; Xin-Xin Yu; Roger H Unger
Journal:  Diabetologia       Date:  2016-04-26       Impact factor: 10.122

10.  The metabolic and hormonal responses to a mixed meal in unrestrained pancreatectomised dogs chronically treated by portal or peripheral insulin infusion.

Authors:  Y Goriya; A Bahoric; E B Marliss; B Zinman; A M Albisser
Journal:  Diabetologia       Date:  1981-07       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.